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ABSTRACT 
The present study designed to investigate the toxicological profile, cardioprotective and in-
vitro thrombolytic activity of novel herbal combination with nigella sativa oil and barley 
water. The acute and sub-acute (28 days) oral toxicity of herbal combination on wister rats 
was performed. All the morphological, hematological, biochemical and hostological 
changes in addition to mortality and body weight changes were recorded. The acute toxicity 
result was shown no significant toxicity and  mortality observed in the both sexes of animals 
upto maximum dose. Hence it may be recommend for clinical utility. 
The sub-acute toxicity result shown no dose related toxicity changes was seen all groups. 
Hence it can be used for chronic treatment. 
Myocardial infarction was induces by the administration of isoproterenol hydrochloride 
(ISO) 85 mg/kg, i.p, the rats were pretreated with the dual herbal combination through the 
oral route. ISO alone, treated rats showed the elevated serum cardiac biomarkers such as 
LDH, CK-MB, SGOT and SGPT due to myocardial damage produced by ISO. This further 
confirmed by histopathological examination of heart tissues. Oral administration of dual 
herbal combination significantly restored the level of serum cardiac markers and other 
altered biochemical parameters. 
An in-vitro thrombolytic model was used to check the clot lysis effect of the the prepared 
dual herbal combination, streptokinase was used as a positive control and water as negative 
control. The study suggests that thrombolytic activity of dual herbal combination could be 
considered as very promising  and beneficial for therapeutic purposes 
Key words: Black seed oil, Hordeum Vulgare, acute and sub-acute toxicity, cadioprotection, 
thrombolysis 
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CHAPTER – I 
INTRODUCTION 
 
Every living cell relies on the surrounding interstitial fluid as the major source of oxygen 
and nutrients and as a place for the disposal of cellular wastes. Levels of gases, nutrients, 
and cellular waste products in the interstitial fluid are kept stable through continuous 
exchange between the interstitial fluid and the circulating blood. The blood must stay in 
motion to maintain the body homeostasis. If blood stops flowing through vessels and 
tissues, its oxygen and nutrient supplies are exhausted quickly, its capacity to carry wastes 
is soon reached, and neither hormones nor white blood cells can get to their intended 
targets. Thus, all of the functions of the cardiovascular system ultimately depend on the 
heart, because it is the heart that keeps circulation of blood. This muscular organ beats 
approximately 100,000 times in a day, propelling blood through the blood vessels.  
 
1.1. Heart and Blood Circulation 
 
Despite its impressive workload, the heart is a small organ; your heart is roughly the size 
of your clenched fist. The heart’s four muscular chambers, the right atrium and left atrium 
and right ventricle and left ventricle, work together to pump blood through a network of 
blood vessels between the heart and the peripheral tissues. The circular network can be 
subdivided into two: the pulmonary circuit, which carries carbon dioxide-rich blood 
(impure blood) from the heart to the gas exchange surfaces of the lungs (alveoli) and 
returns oxygen-rich blood (pure blood) to the heart; and the systemic circuit, which 
transports oxygen-rich blood from the heart to the rest of the body’s cells, returning 
carbon dioxide-rich blood back to the heart.  
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Fig: 1. The circulatory system. 
 
The right atrium receives blood from the systemic circuit, and the right ventricle release 
blood into the pulmonary circuit. The left atrium collects blood from the pulmonary 
circuit, and the left ventricle discharges blood into the systemic circuit. When the heart 
beats, atria contract first, followed by the ventricles. The two ventricles contract at the 
same time and eject equal quantity of blood into the pulmonary and systemic circuits. 
 
Each circuit begins and ends at the heart. Capillaries are small, thin-walled vessels that 
interconnect the smallest arteries and veins. Capillaries are called exchange vessels 
because their thin walls permit exchange of dissolved gases, nutrients and waste products 
between the blood and surrounding tissues. 
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1.2. Structure of the Heart Wall  
 
A section along the wall of the heart reveals three distinct layers:  
 (1) An outer epicardium (visceral pericardium) 
 (2) A middle myocardium, and    
 (3) An inner endocardium. 
 
The epicardium or visceral pericardium; it forms the external surface of the heart. The 
epicardium is a main membrane consisting of a mesothelium covering a supporting layer 
of areolar connective tissue.  
 
The myocardium contains multiple, interlocking layers of cardiac muscle tissue, with 
associated connective tissues, blood vessels, and nerves etc. The relatively thin atrial 
myocardium consists of few layers that form figure-eights as they pass from atrium to 
atrium. The ventricular myocardium is much thicker than atrial myocardium and the 
muscle orientation changes from layer to layer. Superficial ventricular muscles wrap 
around both ventricles; deeper muscle layers spiral around and between the ventricles 
from the attached base toward the free tip, or apex, of the heart (Fig: 2) 
The inner surfaces of the heart, including the valves, are covered by a simple squamous 
epitheliumis called the endocardium (en-do- KAR-de-um; endo-, inside). The 
endocardium is continuous with the endothelium of the particular  attached blood vessels. 
 
1.3. Cardiac Muscle Tissue  
 
The histological characteristics of cardiac muscle tissue give the myocardium and its 
unique functional properties. Cardiac muscle cells, or cardiocytes, are relatively small, 
averaging size 10–20 mm in diameter and 50–100 mm in length. A typical cardiocyte has 
a single nucleus,which is  centrally placed (Fig: 2) 
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Cardiac  muscle cells resemble skeletal muscle fibers, although they are much smaller 
than skeletal muscle fibers in that each cardiac muscle cell contains organized myofibrils 
and the alignment of their sarcomeres produces striations. However, the cardiac muscle 
fibrils are differ from skeletal muscle fibers in several important respects: 
 
Cardiac muscle cells are almost totally dependent on aerobic respiration to obtain the 
needed energy to continue contracting. Hundreds  of mitochondria present in the 
sarcoplasm of a cardiac muscle cell and abundant reserves of myoglobin (to store oxygen). 
Energy reserves are maintained in the form of glycogen and lipid inclusions. 
 
 
 
Fig: 2. Histological Organization of Cardiac Muscle Tissue. 
 
The relatively short T-tubules of cardiac muscle cells do not form triads with the 
sarcoplasmic reticulum. The circulatory supply of cardiac muscle tissue is more extensive 
even than that of red skeletal muscle fiblils. 
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1.4. Cardiovascular Diseases 
 
Cardiovascular diseases (CVDs) are group of disorders of the heart and blood vessels and 
include coronary heart disease (heart attack), cerebrovascular disease, rheumatic heart 
disease and other conditions. Four out of five cardiovascular disease deaths are due to 
heart attacks and strokes. Individuals at risk of CVD may demonstrate raised blood 
pressure, glucose, and lipids as well as overweight and obesity etc
1
.   
 
Cardiovascular Diseases are responsible for over 17.3 million deaths per year and are the 
leading causes of death in the world. Deaths due to heart attacks, strokes and other types 
of CVDs as a proportion of total cardiovascular deaths for males and females
2
 (Fig: 3). 
 
 
 
Fig: 3. Distribution of major causes of death including CVDs 
 
1.5. Pathophysiology of Cardiovascular Diseases 
 
Atherosclerosis is the main underlying pathological processes that leads to heart attacks 
(coronary heart disease) and strokes (cerebrovascular disease). The early changes of 
atherosclerosis develop in childhood and adolescence due to the overall effect of a many of risk 
factors
3-5
. They  include use of tobacco, physical inactivity, unhealthy diet, use of alcohol, 
hypertension, diabetes, raised blood lipid level, obesity, poverty, low educational status, 
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advancing age, male gender, genetic disposition and psychological factors etc. 
 
              
 
Fig: 4- Schematic of sequential progression of coronary artery lesions 
 
 When the process continues, there is thinning of the fibrous cap accompanied by fissuring 
of the endothelial surface of the formed plaque, which may rupture. From the ruptured 
plaque, lipid fragments and cellular debris are released into the vessel lumen. These 
released materials are exposed to thrombogenic agents on the endothelial surface, 
resulting in the formation of a thrombus. The coronary blood vessel or a cerebral blood 
vessel is blocked, when the thrombus is large enough, this results in a heart attack or 
stroke
7, 8
. 
 
Pharmacological assessment of dual herbal combination on cardiovascular system 
 
RVS College of Pharmaceutical Sciences, Sulur   7 
 
 
Fig.5: Pathophysiology of myocardial infarction. 
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Heart attack : When the blood flow to the heart is cut off, due to a thrombus on a 
ruptured atherosclerotic plaque, the dimished supply of oxygen and nutrients can damage 
the heart muscle cells, resulting in a heart attack. When the blood flow is decreased due to 
a blockage, it causes chest pain (angina) due to ischaemia of heart. 
 
       
 
 
 
Fig: 6. Acute myocardial infarct, predominantly of the posterolateral left ventricle. 
 
Stroke: The pathophysiology of ischaemic stroke is more diverse and includes, besides 
thrombus formation in cerebral blood vessels (ischaemic stroke), small vessel disease in 
the brain linked to vascular risk factors. Another cause of stroke is haemorrhage 
(bleeding) due to the rupture of a blood vessel because of uncontrolled high blood 
pressure or atherosclerosis (haemorrhagic stroke). In addition, strokes can also be caused 
by a travelling blood clot. If a person has an irregular heartbeat, blood clots may form in 
the heart and travel along with the blood to the brain. A clot carried to the cerebral 
circulation in this way can be trapped in a cerebral blood circulating route and block the 
blood flow to an area of the brain. 
 
 
Pharmacological assessment of dual herbal combination on cardiovascular system 
 
RVS College of Pharmaceutical Sciences, Sulur   9 
 
1.6. Isoproterenol Induced Myocardial Infarction 
 
Isoproterenol hydrochloride (ISPH), a synthetic catecholamine and β-adrenergic agonist 
that causes severe stress in the myocardium and infarct-like necrosis of the heart muscles
9
. 
ISPH induces myocardial injury by altering the vascular membrane permeability, which 
brings about the loss of functions and integrity of myocardial membranes
10
.  
 
Isoproterenol-induced myocardial necrosis is considered as one of the most widely used 
experimental model to study the beneficial effects of many drugs on cardiac function
11
. 
Catecholamine readily undergoes oxidation and the oxidative products of catecholamine 
are responsible for the myocardial damage
12
. Catecholamines have been shown to increase 
myocardial oxygen consumption and enhance the extents of myocardial damage during 
evolving acute myocardial infarction
13
. Myocardial infarction induced by isoprenaline 
hydrochloride [isoproterenol; L-β-(3,4-dihydroxyphenyl)-α- isopropylaminoethanol 
hydrochloride], a β- adrenergic agonist, shows many metabolic and morphologic 
aberrations in the myocardium of experimental animal’s heart is similar to those observed 
in myocardial infarction in human
14
. When the large dose of catecholamines is 
administered, particularly isoproterenol hydrochloride to the experimental animal 
constitutes a rapid and reproducible means of provoking myocardial ischemia (Fig :6).  
 
Isoproterenol-induced MI serves as a well-standardized model because the 
pathophysiological changes following isoproterenol administration are comparable to 
those taking place in human heart
15
. Intraperitoneal administration of isoprenaline can 
produces ischemic lesions and increases lipid peroxidation in the myocardium, which 
plays a significant part in the pathogenesis of myocardial dysfunction
16
. Alterations in the 
activities of antiperoxidative enzymes [ie ; superoxide dismutase (SOD) and catalase 
(CAT)] and glutathione dependent antioxidant enzymes [glutathione peroxidase (GPX) 
and glutathione-S-transferase (GST)] have been reported in experimentally ISPH induced 
myocardial infarction in rat model
17
. AMI causes a detectable ris in the plasma 
concentration of cardiac marker enzymes, which are normally concentrated  within cardiac 
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cells. The enzymes most widely used in the detection of MI are, creatine kinase (CK-MB), 
aspartate aminotransferase (AST) and lactate dehydro-genase (LDH) etc. An increased 
level of free radical generating system and malondialdehyde (MDA) and lowered levels of 
free radical scavenging systems seem to have critical role in the ischemic heart 
condition
18
. 
 
 
 
Fig.7: Isoproterenol induced myocardial damage 
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1.7. Diagnosis of Acute Myocardial Infarction 
 
In the clinical assessment of coronary heart diseases, electrocardiography is an essential 
adjunct instead of clinical history and physical examination. A proper diagnosis (rapid and 
accurate) in patients with acute myocardial infarction is vital, as expeditious reperfusion 
therapy can improve prognosis. ST segment elevation in two or more anatomically 
contiguous leads is the most frequently used electrocardiographic criterion for identifying 
acute myocardial infarction.  The elevation ST segment associated with an evolving 
myocardial infarction is often readily identifiable, but a knowledge of the common 
―pseudo‖ infarct patterns is essential to avoid the unnecessary use of thrombolytic 
therapy
19 
 
 
Echocardiogram and angiogram with dye (contrast method by using X-ray) also used to 
assess or get detailed information of the arteries in the heart. 
 
1.8. Laboratory Evaluation
 
 
Quantitative or qualitative evaluation of specific blood protein levels that leak out of 
fatally injured myocytes; these molecules include myoglobin, cardiac troponins T and I, 
the MB fraction of creatine kinase (CK-MB), lactate dehydrogenase, and many others ( 
Fig: 8)
20
.  If the myocardial injury is established when blood levels of these cardiac 
biomarkers are increased in the clinical setting of acute ischemia. The intracellular 
location, molecular weight, the blood flow, lymphatic drainage in the area of the infarct, 
and the rate of elimination of the marker from the blood are some factors which affect the 
appearance of these markers in the peripheral circulation. 
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Fig. 8: Specific Blood Protein Levels That Leak Out Of Fatally Injured 
Myocytes. 
Cardiac-specific proteins like Troponins I and T (proteins that regulate calcium-mediated 
contraction of cardiac and skeletal muscle) are the most sensitive and specific biomarkers 
of myocardial damage .They are not not normally detectable in the circulation. 
The level of both proteins begins to rise at 2 to 4 hours and peak at 48 hours once the MI 
occur. Formerly the ―gold standard,‖ cardiac creatine kinase remains useful.  Creatine 
kinase  (composed of two isoforms designated ―M‖ and ―B‖) , an enzyme that is present in 
brain, myocardium, and skeletal muscle. MB heterodimers principally in cardiac muscle, 
with minute quantity also being found in skeletal muscle. MM and BB are the 
homodimers found in the cardiac, skeletal muscle, brain, lung, and many other tissues 
respectively
21
. 
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Fig.9: Release of cardiac markers after acute myocardial infarction (AMI). 
 
The rised CK-MB (elevated within 2 to 4 hours of the onset of MI, peaks at about 24 
hours) returns to normal within approximately 72 hours. The diagnostic sensitivities of 
cardiac troponin and CK-MB measurements are similar in the MI in early stage. Elevated  
troponin levels persist for approximately 7 to 10 days after acute MI, well after CK-MB 
levels have returned to normal.Troponin and CK-MB levels peak earlier in patients whose 
hearts are successfully reperfused, because proteins are washed out of the necrotic tissue 
more rapidly. Unchanged levels of CK-MB and troponins over a period of 48 hours 
essentially excludes the diagnosis of MI
21
. 
Following an MI, the levels of Aminotransferases such as Aspartate aminotransferase and 
Alanine aminotransferase  (AST, or SGOT ang SGPT) also elevated in the serum.  L-
Lactate dehydrogenase is a tetrameric enzyme whose four subunits occur in two isoforms, 
designated H (for heart) and M (for muscle). Isozymes of lactate dehydrogenase (LDH-1) 
are used to detect myocardial infarctions
22
. 
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1.9. Treatment of Myocardial Infarction 
Medication/medication 
class 
Use Comments 
Antihypertensive agents 
ACE inhibitors All patients with hypertension, 
diabetes mellitus, chronic 
kidney disease, or left 
ventricular dysfunction 
Decrease mortality 
Angiotensin receptor 
blockers 
All patients with hypertension, 
diabetes, chronic kidney 
disease, or left ventricular 
dysfunction, and in whom 
ACE inhibitors are not 
tolerated 
No additional benefit 
compared with ACE 
inhibitors; may be 
considered in combination 
with ACE inhibitors for 
heart failure with left 
ventricular dysfunction 
Beta blockers All patients with history of MI, 
acute coronary syndrome, or 
left ventricular dysfunction, 
unless contraindicated 
Decrease mortality; avoid 
beta2 selective agents and 
agents with intrinsic 
sympathomimetic 
properties 
Calcium channel 
blockers 
Patients in whom beta blockers 
are not tolerated 
Avoid short-acting 
nifedipine (Procardia)  
Nitrates Patients with anginal 
symptoms despite use of beta 
blockers or calcium channel 
blockers 
Evidence lacking on 
mortality benefit 
Antiplatelet agents 
Aspirin All patients (75 to 162 mg per 
day), unless contraindicated 
Decreases nonfatal MI, 
strokes, vascular deaths 
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Clopidogrel (Plavix) Patients in whom aspirin is 
contraindicated or not tolerated 
Approved for acute 
coronary syndrome, recent 
MI, stroke, peripheral 
arterial disease, or coronary 
stent placement 
Lipid-lowering agents 
Ezetimibe (Zetia) Patients who have not achieved 
LDL goal despite statin 
therapy or who are intolerant 
of statins 
Evidence lacking on 
mortality benefit 
Fibrates Patients with triglycerides of 
200 to 499 mg per dL (2.26 to 
5.64 mmol per L) and non-
HDL > 130 mg per dL (3.37 
mmol per L); triglycerides ≥ 
500 mg per dL (5.65 mmol per 
L) 
Reduction to non-HDL < 
100 mg per dL (2.59 mmol 
per L) reasonable; treat if 
triglycerides ≥ 500 mg per 
dL to prevent pancreatitis 
Nicotinic acid Same as for fibrates; 
triglycerides of 200 to 499 mg 
per dL and non-HDL > 130 mg 
per dL; triglycerides ≥ 500 mg 
per dL 
Same as for fibrates; 
reduction to non-HDL < 
100 mg per dL reasonable; 
treat if triglycerides ≥ 500 
mg per dL to prevent 
pancreatitis 
Statins Patients with a baseline LDL ≤ 
100 mg per dL 
Initiate with lifestyle 
measures; reduction to LDL 
< 70 mg per dL (1.81 mmol 
per L) or high-dose statin 
therapy reasonable 
 
Table .1: Pharmacotherapy for Myocardial Ischemia 
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1.10. Haemostasis and Thrombosis 
Hemostasis is derived from a Greek word, which means stoppage of blood flow. The 
combination of cellular and biochemical eventsthat function together to maintain the 
nature of blood the liquid form within the veins and arteries thereby prevent the blood loss 
following injury through the formation of blood clot.
23,24
. Whenever a blood vessel is 
severed or ruptured, hemostasis is achieved by several mechanisms they includes vascular 
constriction, formation of a platelet plug, formation of a blood clot as a result of blood 
coagulation, and eventual growth of fibrous tissue into the blood clot to close the hole in 
the vessel permanently. This will stop bleeding and are eventually dissolved through the 
fibrinolytic process. As a result of this mechanism, there is delicate balance between the 
production and dissolution of clot during the haemostatic process. Any disturbance in this 
balance may precipitate thrombosis or hemorrhage as a result of hypocoagulation or 
hypercoagulation  respectively
25,26
.  Process of hemostasis is categorized as either a 
primary or secondary process.  
 
Fig 10: The Haemostatic Plug Formation 
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Primary hemostasis involves the response of the vascular system and platelets to vessel 
injury
4
. It takes place when there are injuries to small blood vessels during which the 
affected blood  vessels contract to seal off the wound and platelets are mobilized, 
aggregate, and adhere to components of the subendothelium of the vasculature. Presence  
of various factors such as von Willebrand factor (vWF) and platelet receptors (IIb/IIIa and 
Ib/IX)are required for the adheasion of platelets. Further extra platelets are attracted to the 
site of injury by the release of platelet granular contents, such as adenosine diphosphate 
(ADP). The interaction of fibrinogen stabilizes the formed platelet plug. 
 
So a defect in the function of platelet or von Willebrand’s disease (vWD) may result in 
debilitating and sometimes fatal hemorrhage 
23
. Secondary hemostasis involves the 
response of the coagulation system to vessel injury
26
.  It is necessary to control bleeding 
from large wounds and is a continuation of the primary hemostatic mechanism.Whereas 
theplatelet plug formation is the primary hemostatic result and the outcome of secondary 
hemostasis is the formation of a thrombus. 
 
 
Fig. 11: Thrombus Formation 
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1.11. Thrombus vs. Embolus 
 
A clot in the blood that adheres to a vascular lumen is called a thrombus, whereas an 
intravascular clot that floats in the blood is termed an embolus. Thus  an embolus may 
generated as a result of a detached clot that floats in the blood. This two forms also 
dangerous, because, they may occlude in the blood flow route and deprive tissues of 
oxygen and nutrients
27
. 
                       
 
Fig. 12: Virchow's triad in thrombosis 
 
1.12. Types of Thrombosis 
There are two distinct forms of thrombosis, each of which can be presented by several 
subtypes. 
1.13. Venous Thrombosis (Phlebothrombosis)
 
  
Venous thrombosis is triggered by the blood stasis or inappropriate activation of the 
series of coagulation cascade, frequently as a result of a defect in the normal hemostatic 
defense mechanisms 27. Majority of venous thrombi occur in the superficial or deep veins 
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of the leg
28
. Although these type thrombi can cause local congestion, swelling, pain, and 
tenderness, they rarely embolize.  
Deep venous thrombosis (DVT) in the larger leg veins—at or above the knee (e.g., 
popliteal, femoral, and iliac veins)—is more serious because such thrombi more often 
embolize to the lungs and may produce pulmonary infarction. At the same scenario they 
can cause local pain and edema, venous obstructions from DVTs can be rapidly offset by 
collateral channels. Approximately 50% of affected individuals DVTs are asymptomatic. 
They are recognized only in retrospect after embolization
21
. 
The common predisposing factors are bed rest and immobilization (because they reduce 
the milking action of the leg muscles, resulting in reduced venous return), and congestive 
cardiac failure (also a cause of impaired venous return). Trauma, surgery, and burns not 
only immobilize a person but are also associated with vascular disturbence, procoagulant 
release from injured tissues, increased hepatic synthesis of factors of coagulation, and 
altered t-PA production. Tumor-associated inflammation and coagulation factors (tissue 
factor, factor VIII) and procoagulants (e.g., mucin) released from tumor cells and they all 
contribute to the increased risk of thromboembolism in disseminated cancers, so-called 
migratory thrombophlebitis or Trousseau syndrome
29, 30
. Regardless of the specific clinical 
setting, advanced age also increases the risk of DVT. 
 
Different classes of deep vein thrombosis are, 
 
 Portal vein thrombosis 
 Renal vein thrombosis 
 Jugular vein thrombosis 
 Cerebral venous sinus thrombosis 
 Paget schroetter disease (obstruction of an upper extremity vein by the 
thrombus)               
 Budd chiari syndrome (blockage of the hepatic vein or the inferior 
venacava)    
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1.14. Arterial and Cardiac Thrombosis 
Atherosclerosis is one of the major cause of arterial thromboses, because it is associated 
with loss of endothelial integrity and with abnormal vascular flow (see Fig.12: A ). 
Myocardial infarction can predispose to cardiac mural thrombi by causing dyskinetic 
myocardial contraction as well as damage to the nearest endocardium (see Fig. 12:B), and 
rheumatic heart disease may engender atrial mural thrombi. Besides local obstructive 
consequences, cardiac and aortic mural thrombi can also peripherally embolizes. Although 
any  of the tissues can be affected, the brain, kidneys, and spleen are particularly likely 
targets because of their rich blood supply
21
.    
Arterial thrombosis most often formed in medium-sized vessels rendered thrombogenic by 
surface lesions on endothelial cells caused by atherosclerosis and this usually consists of a 
platelet-rich clot.  
 
Fig. 13: A) Thrombus in the left and right ventricular apices, overlying white 
fibrou scar. B) Laminated thrombus in a dilated abdominal aortic aneurysm. 
 
1.15. Stroke  
A stroke is the rapid decline of brain function due to a disturbance in the supply of blood 
to the brain. This can be due to ischemia, thrombus, embolus (a lodged particle) or 
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haemorrhage (a bleeding). In thrombotic stroke, a thrombus (a blood clot) usually forms 
around atherosclerotic plaques. Since blockage of the artery is gradual, onset of 
symptomatic thrombotic strokes is slower. Thrombotic stroke can be divided into two 
categories : 
 Large vessel disease 
 Small vessel disease 
The former affects vessels such as the internal carotids, vertebral and the circle of willis. 
The later can affect the smaller vessels such as the branches of the circle of willis. 
1.16. Myocardial Infraction  
Myocardial infraction is caused by an infract (death of tissue due to ischemia), often due 
to the obstruction of the coronary artery by a thrombus. Myocardial infraction can quickly 
become fatal if emergency medical treatment is not received promptly. If diagnosed within 
12 hour (hr) of the initial episode (attack) then thrombolytic therapy is initiated. 
1.17. Diagnosis of Myocardial Infarction 
The initial step in making the diagnosis of a blood clot is obtaining a patient history. The 
blood  clot a does not cause any problem but the location of the blood clot and its effect on 
blood flow that causes symptoms and signs. 
If a blood clot or thrombus is a consideration, the history may expand to explore risk 
factors or situations that might put the patient at risk for forming a clot. Venous blood 
clots often develop slowly with a gradual onset of swelling, pain and discolouration. 
Symptoms of a venous thrombus will often progress over hours. Arterial thrombi occurs 
as an acute event. Tissues need oxygen immediately and the loss of blood supply creates a 
situation in which symptoms begin immediately.  
There may be symptoms that precede the acute artery blockage that may be the warnings 
signs of the potential future complete occlusion of the blood vessel. 
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 Patients with an acute heart attack (myocardial infraction) may 
experience angina in the days and weeks prior to the heart attack. 
 Patients with peripheral artery disease may have pain with walking 
(claudication) and a transient ischemia attack, mini stroke may precede a 
stroke. 
Physical examination can assist in providing additional information that may increase the 
suspicion for a blood clot. 
1.18. Thrombolytic Agents
31 
 
 
Table .2: List of Thrombolytic Agent 
 
 
   Generation 
 
Fibrin specific 
 
Nonfibrin specific 
First ……………. 
……………. 
Streptokinase 
Urokinase 
Second 
 
Recombinant tissue 
plasminogen activator (t-PA) 
Prourokinase (scu PA) 
 
Third 
Alteplase  
APSAC Tenecteplase (TNK-tPA) 
Reteplase 
Monteplase 
Lanoteplase 
Pamiteplase 
Staphylokinase 
Desmoteplase 
(Bat-PA) 
Chimeric thrombolytics 
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1.19. Thrombolytic Therapy in Acute Myocardial Infarction 
 
Streptokinase and front-loaded alteplase regimens are commonly used for thrombolysis in 
acute myocardial infarction (AMI)
32
. The success of the therapy is limited by reocclusion 
because reperfusion is not always achieves3
3,34
. The balance between prothrombotic and 
thrombolytic processes can be shifted toward thrombolysis by administration of 
plasminogen activators; there by  procoagulant effects of such drugs have been reported
.35–
43 
.These side effects are important because of a procoagulant state in acute coronary 
syndromes
43-48
. 
   
Thrombin  activation was markedly increased in patients with AMI and thrombolytic 
therapy associated with failure to open the occluded coronary artery and with a high 
reocclusion rat. No direct data on plasmin activation are available in this situation, but a 
recent clinical study measuring indirect plasmin markers proved the activation of the 
kallikrein– contact-phase system after streptokinase in patients with AMI45.    
 
1.20. Adverse Effects of Thrombolytic Therapy 
 
There are number of side effect which may occur following the administration of  
thrombolytic agents. With the exceptions of urticaria (due to an allergic reaction) and the 
effects of reperfusion, all side effects may be lumped into one category, that is 
hemorrhage. Whether it is intracranial, conjunctival, internal, etc., it is bleeding that is the 
major side effect. Handle these patients very gently to avoid these problems. 
 
1.21. Herbal Remedies for Cardiovascular Diseases 
 Ever since the birth of mankind there has been a relationship between life, disease   and 
the nature. Primitive men started studying diseases and its counter remed. 
 
Ayurveda is a comprehensive natural health care system that has been originated in India 
more than 5000 years ago
49
. Herbal medicines are being used by about 80% of the world 
Pharmacological assessment of dual herbal combination on cardiovascular system 
 
RVS College of Pharmaceutical Sciences, Sulur   24 
 
population primarily in the developing countries for their primary health care needs. They 
have stood the test of time for their safety, efficacy, cultural acceptability and rare side 
effects. The active chemical constituents present in them are a part of the physiological 
functions of living flora and hence they are believed to have better compatibility with the 
human body. Ancient literature also mentions plant based medicines for age-related 
diseases namely memory loss, osteoporosis, diabetic wounds, immune and liver disorders, 
etc. for which no modern medicine or only palliative therapy is available. These drugs are 
made from renewable resources of raw materials by eco-friendly processes and will bring 
economic prosperity to the masses growing these raw materials
50
. The use of plants for 
healing purposes predates human history and forms the origin of much modern medicine. 
Many conventional drugs originated from plant sources: a century ago, most of the few 
effective drugs were plant based. Examples include aspirin (willow bark), digoxin (from 
foxglove), quinine (from cinchona bark), and morphine (from the opium poppy), 
vincristin, vinblastin, pancitaxel..etc
51
. 
  
Plants are rich in a variety of compounds. Many of them are secondary metabolites and 
include aromatic substences, most of which are phenols or oxygen substituted  phenol 
derivatives such as tannins. Many of these compounds have antioxidant properties. 
Ethnobotanicals are important for pharmacological research and drug development, not 
only when plant constituents are used directly as therapeutic agents, but also as starting 
materials for the synthesis of  various drugs or as models for pharmacologically active 
compounds
52
. 
 
1.22. Cardioprotective Herbs 
 
More than 2000 plants have been mentioned in the Traditional (Herbal/Alternative) 
systems of medicine and some of these are providing comprehensive relief to the people 
suffering from cardiovascular diseases, specially ―hyperlipidemia‖ and ―ischemic heart 
disease‖. WHO reports that around eighty percent(80%) of the global population still 
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relies on botanical drugs and several herbal medicines have advanced to clinical use in 
modern times
53
. 
 
1.23. Herbal Cardioprotective Compounds  
 
Recent studies have shown that a number of plant products including polyphenols, 
terpenes and various plant extracts exertes free radical scavenging activity. There is also a 
considerable amount of evidence revealing an association between individuals who have a 
diet rich in fresh fruits and vegetables and the decreased risk of cardiovascular diseases 
and certain forms of cancer also
54-55
.  
 
The naturally occurring methoxyphenol apocynin has been found to inhibit NADPH 
oxidase upon activation by enzyme peroxidases (e.g. soybean peroxidase, 
myeloperoxidase) or ROS under mild reaction conditions. Upon catalyzed activation of 
peroxidase , the apocynin oxidation products act to block the assembly and activation of 
NADPH oxidase. Although the mechanism of inhibition of NADPH oxidase remains 
largely unknown, apocynin’s high effectiveness and low toxicity makes it a promising 
lead compound in the development of new therapeutic substense for cardiovascular 
diseases
56
. 
 
Examples of herbal agents shows cardio vascular activity: Garlic preparations are taken by 
many patients because of their anti-lipid and anti-platelet effects, significant factors in the 
prevention of thrombus formation
57-59
.  
 
The allicin derivative of garlic root has been shown to enhance fibrinolytic activity and 
inhibit  the platelet aggregation in patients having coronary artery disease
60-62
, either via a 
dose-dependent alteration in the production of arachidonic acid metabolites (i.e. inhibition 
of thromboxane formation in platelets
61,63,64
 or by altering physiochemical properties (i.e; 
the ADP receptor) of the platelet membrane
65,66
. 
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Consumption of polyphenols in the diet has been shown to reduce the likelihood of 
morbidity and mortality from coronary artery disease. One way in which polyphenols are 
thought to act is through the inhibition of lipid peroxidation of low density lipoprotein 
(LDL) 
67
. Dietary supplements rich in polyphenols, such as black and green tea
68
, olive oil 
69
, red wine, and licorice root extract
70
, are associated with an increased resistance of 
plasma LDL oxidation
71
. 
 
1.24. Natural Thrombolytic Remedies 
 
A regular intake of blood thinning foods against the cause of blood clots (anti- thrombotic 
diet) offers a convenient and effective method of prevention of acute thrombotic events. 
Foods and blood thinning medications have the following way to acting to prevent heart 
attack or stroke. 
Anti clumbingof blood 
Prevent blood clot formation 
Clot dissolving ability 
Natural blood thinning foods include strawberries, tomatoes, mulberries, onions, carrots, 
common thyme and rosemary etc. 
 
 
1.25. Nigella Sativa:  Pharmacognostic Description 
 
Nigella sativa also known as Black seed is an herbaceous annual plant and it is indigenous 
to the Mediterranean region. Black cumin is One of the miracle herbs plant that has been 
considered as prophetic medicine is Habbatus sauda (Nigella Sativa). Seeds of Nigella 
sativa L. (Ranunculaceae) or black cumin, are used in folk (herbal) medicine all over the 
world for the treatment and prevention of many of diseases and conditions that include 
asthma, diarrhea and dyslipidaemia. N. sativa seeds are used to prepare highly prized 
nutritive oil. Although on the world scale Nigella seed oil does not really have a 
significant economic market share, yet, it nevertheless constitutes a niche market whose 
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size is constantly growing due to its alleged pharmacological Plant extracts and essential 
oil showed a broad range of pharmacological activities
72
. 
 
1.26. Taxonomic classification of Nigella sativa 
 
Kingdom  : Plantae. 
Subkingdom  : Tracheobionata that is, vascular plant. 
Supervision  : Spermatophyte. 
Order  : Ranunculales. 
Family  : Ranunculaceae-Butter cup family. 
Genera  : Nigella. 
Species  : sativa. 
  
 
Fig 14: Nigella Sativa Flower and Seed. 
 
1.27. Synonyms and Habitat
73 
 
Black cumin, Black Caraway, Fennel Flower, Nutmeg Flower, Black seed,  Roman 
Coriander, Damascena, Devil in-the-bush, Wild Onion Seed.  N. sativa is native to 
Southern Europe, North Africa and Southwest Asia and it is cultivated in  many countries 
in the world like Middle Eastern Mediterranean region, South Europe, India, Pakistan, 
Syria, Turkey, Saudi Arabia. 
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1.28. Morphology of the Plant
73 
 
N. sativa is an annual flowering plant grows at 20-90 cm tall, with finely divided leaves; 
the flowers having5-10 petals and white, yellow, pink, pale blue or pale purple color. The 
fruit is a large and inflated capsule consists of 3-7 united follicles, each containing several 
seeds. Seeds are small dicotyledonous, trigonus, angular, tubercular, black externally and 
white inside, odor slightly aromatic and taste bitter. 
 
1. 29. Nigella sativa  Seed 
 
Seeds are small dicolyledonous, trigonus, angular, regulose-tubercular, 2-3.5 × 1-2 mm, 
white inside covered by black external coating. Transverse section of seed shows single 
layered epidermis consisting of elliptical, thick walled cells, covered externally by 
papillose cuticle and filled with dark brown contents. 2-4 layers of thick walled 
tangentially elongated parenchymatous cells have been seen just near to the epidermis, 
followed by reddish brown pigmented layer composed of thick walled, rectangular 
elongated cells
74
. 
1.30. Active Constituents 
Thymoquinone, the active constituent of Nigella sativa seeds, is pharmacologically active 
quinone, which prevents oxidative injury in various in vitro and in vivo studies in rats
75,76
 
and also has been suggested that thymoquinone may quench oxidant radicals and prevents 
membrane lipid peroxidation in tissues 
77
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Fig. 15: Different chemical components of Nigella Sativa 
 
 
1.31.   Pharmacological Effects for Potential Healthcare 
 
Traditionally its seeds and oil are used in several diseases. The seeds are considered as 
bitter, pungent, aromatic, appetizer, stimulant, diuretic, emmenagogue, galactogogue, 
anthelmintic, acride, thermogenic, carminative, deodorant, digestive, constipating, 
febrifuge, exppectorent, purgative,  antihypertensive, bronchodilator, gastroprotective, 
hepatoprotective, antidiabetic, anticancer and immunomodulatory, analgesic, 
antimicrobial, analgesics and anti-inflammatory, spasmolytic, renal protective and 
antioxidant properties.
78
 
 
1.32. Hordeum  Vulgare: Botanical Description
79
 
 
Barley is a member of the grass family Triticeae. Wheat and rye also fall into this grass 
family. In total, there are thirty-one barley species. Of the thirty-one, three-fourths are 
perennial grasses, blooming every summer and dying back in the winter. Although there 
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are so many types of barley, scientists hypothesize that they all originated from one 
ancestor plant, the Hordeum spontaneum. 
 
 
 
Fig 16:  Barley plant and grains. 
 
 
1.33. Taxonomic Classification of Hordeum vulgare 
 
Kingdom  : Plantae - Plants  
Subkingdom  : Tracheobionta - Vascular plants  
Superdivision : Spermatophyta - Seed plants 
Division  : Magnoliophyta - Flowering plants  
Class  : Liliopsida – Monocotyledons 
Subclass  : Commelinidae  
Order  : Cyperales  
Family  : Poaceae - Grass family  
Genus  : Hordeum – barley 
Species  : H. vulgare 
 
Barley is an annual grass that strands 60-120 cm tall. Barley has two types of root 
systems, seminal and adventitious. The stems are erect and made up of hollow, cylindrical 
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internodes separated by the nodes, which bear the leaves.A mature barley plant consists of 
lateral stem and 2-5 branch stems, called tillers
80
. 
 
Barley leaves are linear 5-15 mm wide and are produced alternate sides of the stem. The 
leaf structure consists of the sheath, blade auricles and ligules. The sheath surrounds the 
stm compleately. The ligules and auricles distinguishes the barley from other cereals as 
they are smooth, envelop the stem and can be pigmented with anthocyanins
81
. 
 
Barley cell walls encapsulate starch granules embedded in a protein matrix. With thin cell 
walls and loose packing of endosperm, the large mealy grains allow a rapid water up-take 
and uniform distribution of water and enzymes synthesised during germination. On the 
contrary, due to thick cell walls and tightly packed endosperms, small steely grains retard 
mass transfer in the endosperm. Large, plumb kernels are desired for malting. The fraction 
above the 2.5 mm sieve is normally used for malting and the rest is included in the feed 
fraction. A larger uniform grain size is desired because it enables homogenous water up-
take and modification
79
. 
 
1.34. Nutritional Information 
 
One cup (237 ml) of cooked pearled barley contains 193 calories, while the whole-grain 
(hulled) form contains 270 calories and contains as much protein as a cup (237 ml) of 
milk. 
 
1.35. Pharmacological Effects for Potential Healthcare 
 
N. sativa has been extensively studied for its biological activities and shown to possess 
wide spectrum of activities such as diuretic, antihypertensive, bronchodilator, 
gastroprotective, hepatoprotective, antidiabetic, anticancer and immunomodulatory, 
analgesic, antimicrobial,analgesics and anti-inflammatory, spasmolytic, renal protective 
and antioxidant properties
79
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CHAPTER – II 
LITERATURE REVIEW 
 
1. Kaur et al (2013) reported that More than 2000 plants have been listed in the 
Traditional (Herbal/Alternative) systems of medicine and some of these are 
providing comprehensive relief to the people suffering from cardiovascular diseases, 
specially ―hyperlipidemia‖ and ―ischemic heart disease‖.82 
 
2. Francis et al (2002) reported that In the clinical assessment of chest pain, 
electrocardiography is an essential adjunct to the clinical history and physical 
examination. The ST segment elevation associated with an evolving myocardial 
infarction is often readily identifiable, but a knowledge of the common ―pseudo‖ 
infarct patterns is essential to avoid the unnecessary use of thrombolytic treatment.
83 
 
3. Marwa A et al (2013) investigated as Niella Sativa Oil supplementation attenuates 
lead-induced cardio toxicity by mechanisms related, at least in part, to its ability to 
decrease the pro inflammatory cytokines, oxidative stress and cardiac tissue damage 
and preserve the activity of antioxidant enzymes. N. sativa could serve as a true 
functional food and may positively affect health promotion via reducing 
cardiovascular risk.
84 
 
4. Hosseini et al (2014) found that the extracts of  nigella sativa with glycyrrhiza 
glabra and zingiber officianalis have some protective effects against DOX-induced 
toxicity in cardiomyocytes with similar efficacies, but with different potencies. 
However, NGZ produced much higher protective effect via reducing oxidative stress 
and inhibiting of apoptotic induction processes. Further investigations are needed to 
determine the effects of NGZ on DOX chemotherapy.
85 
 
5. Kaleem et al (2008) indicated that oral administration of  ethanolic extraction of 
nagella sativa seeds to streptozotocin induced diabetic rats 30 days significantly 
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reduces the elevated levels of blood glucose, lipids, insulin and improved the altered 
levels of lipid peroxidation products and antioxidant enzymes like catalase, super 
oxide dismutase,reduced glutathione and glutathione peroxidase in liver and 
kidney.
86 
 
6. Kaatabi, et al (2012) investigated that nigella sativa suppliments at a dose of 2g/ 
day for 12 weeks may improve the dyslipidemia associated with type 2diabetis 
patients. So nigella sativa is a potential protective natural agentagainst 
atherosclerosis and cardiovascular complication in the patients.
87 
 
7. Abou Gabal et al (2007) found that the treatment of the animals with N. sativa 
improved both genotoxicity and ultrastructural changes induced by the two dose 
levels of CCl4.
88 
 
8. Amr A. Rezq (2014) investigated The effects of Nigella Sativa Extract (NSE), 
Nigella Sativa Oil (NSO) and Vitamin E (Vit. E) and the combination of NSE or 
NSO with Vit. E on potassium bromate (KBrO3)-induced oxidative stress in male 
rats. According to his conclussion oral administration of NSE or NSO alone and in 
combination with vitamin E exhibited weight gain and feed efficiency ratio and 
lowered the elevated serum levels of total cholesterol, triglycerides, AST, ALT, urea 
nitrogen, uric acid and creatinine
89. 
 
9. Ahmed Jasim Mohammad (2015) studied the role of black seed oil and olive oil on 
the cholesterol and total protein and triglycerides by using  twenty-five rabbit,  
divided into five totals: total control of outdoor graduation was drenched just water. 
The first treatment series: a dose of black seed oil 25% and 75% of olive oil  and the 
second group outdoor graduation was drenched black seed oil 50% and 50% olive 
oil. Then third treatment group outdoor graduation was drenched black seed oil 75% 
and 25% of olive oil. And group fourth treatment 100% outdoor graduation was 
drenched black caraway seeds only. He noticed the effect of treatment after the 
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duration of study, that is low cholesterol in the group treated first, second and third, 
depending on the concentration of black seed oil and olive oil, while increases when 
there are black cumin oil only in the fourth set. And  the level of total protein in 
group treatment first, second and third while dipping in the fourth treatment group 
outdoor graduation was drenched black caraway seeds only. Low triglycerides in 
group treatment first, second and third, depending on the concentration of black seed 
oil and olive oil, while increases when there are black cumin oil only in Group IV 
according to his suggestion the large term and high concentration supplementation of 
black seed oil reduced plasma liquid cholesterol and triglyceride while total protein 
increased,  from these point of view , an intake of black seed oil combination with 
olive oil feasible therapeutic strategy for prevention and treatment of patient with 
hyperlipidemia and obesity.
90 
 
10. Neelam Chaturvedi et al (2011) suggested that natural products such as cereals are 
likely to form the basis of nutraceutical as its revolution represents an enormous 
opportunity for growth and expansion. Wheat, rice, millets, barley, oat, buckwheat 
,corn ,sorghum, flaxseed psyllium, brown rice, and products are notify the most 
common cereal based functional foods and nutraceuticals. The nutrients in the 
cereals have identified prospective for reducing the risk of coronary heart disease, 
diabetes, tumor incidence, cancer risk, blood pressure, reduces the rate of cholesterol 
and fat absorption, delaying gastrointestinal emptying and providing gastrointestinal 
health
91
.
 
 
11. Vaclav Vetvicka et al (2007) showed that with respect to natural glucans, there is a 
yes-or-no effect suggesting that highly purified and highly active glucans will have 
pleiotropic impact, whereas poorly isolated and/or less active glucans will have only 
mediocre biological properties
92
.
 
 
12. Mokhtar I et al (2006) demonstrated that treatment of diabetic rats with barley and 
some of its components (chromium and amino acids) could repair liver damage and 
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restoring pancreatic b-cells deformation. This was manifested by the biochemical 
and immunoassay results and electron microscope study where the hypoglycemic 
and hypolipidemic action of barley may be due to its contents generally and in 
specific to its content of chromium and/or amino acids
93
.
 
 
13. Gul et al (2014) demonstrates that HV possesses activities against all human platelet 
agonists used in this study except ADP, and inhibited both COX and LOX pathways 
of AA metabolism. It also elevated the activities of SOD and GPx. However, these 
activities were distributed in various fractions. Therefore, it is unlikely that a single 
phytocompound is responsible for all these activities. Some fractions of HV showed 
more potent activities than others while certain fractions were almost completely 
devoid of anti-inflammatory effect (aqueous). Interestingly, crude extract was unable 
to enhance GPx activity while n-hexane fraction which was obtained from the 
fractionation of crude extract, caused significant elevation of GPx activities
94
.
 
 
14. Consumption of soluble fiber improves risk factors for cardiovascular diseases and 
diabetes mellitus. It also provides satiety value. Soluble fiber reduces plasma 
cholesterol concentrations, lowers postprandial plasma glucose and insulin 
concentrations and ameliorates insulin resistance. Most research on soluble fiber has 
focused on oats. Barley, another excellent soluble fiber source, has received little 
attention. Many forms of barley or barley extracts have not been investigated in 
human subjects. Thus, research is needed to assess the health effects of human 
consumption of barley and barley products including germinated barley foodstuff, 
barley co-products, and barley Nutrim. This paper describes research that uses 
controlled feeding of human subjects to determine the ability of barely and barley 
products to affect risk factors for cardiovascular disease and diabetes in normal 
weight and overweight adults. Moreover, the research will assess the ability of diets 
high in soluble fiber to aid in weight loss and maintenance of weight-reduced 
subjects
95
.
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15. Inas E Darwish et al (2013) studied that barley extract orally administered had 
reinforced the venlafaxine antidepressant and antioxidant effect when combined 
together in experimental induced chronic mild stress model in rats. Their 
compliment effect had explored further on brain serotonin and magnesium serum 
level. No significant effect on brain nitric oxide level had been proved in the current 
study by any of the treated regimen
96
.
 
 
16. Saurabh Arjariya et al (2013) evaluated that the potential toxicity of Terminalia 
catappa (almond) in rats. Acute toxicity of the Terminalia catappa extract found to 
be safe at the doses 2000mg/kg body weight orally as per OECD guidelines No.423. 
No dose related toxicities are obsereved in his14 days investigation.  In the chronic 
toxicity study, oral administration of the aqueous extract of Terminalia Catappa linn 
at doses of 100, 200 and 400 mg/kg once in a week for 6 weeks to rats. There was no 
toxicity/ death was observed at the dose of 2000mg/kg b.w. In the chronic toxicity 
study, no significant treatment-related changes in the levels of hematological and 
biochemical parameters. It suggests that the aqueous extract of Terminalia catappa 
linn. does not have significant toxicity
97. 
 
17. Rabiatul et al (2014) reported that there is no statistically significant effect of  
concentration of 0.1, 0.5 and 2.0g/kg cinnamon aqueous extract (CE)  on oral sub 
acute toxicity study on behaviour, mortality, water intake, food consumption, weight 
gain, internal organs weight (liver and kidney) and heamatological parameters 
during treatment and post-treatment periods. But a  slight decreased in kidney and 
liver weight of rats treated with 0.5g/kg and slight decreased in liver weight of rats 
treated with 2.0g/kg, during post-treatment period.  So these evaluation study 
suggested that the CE is low to moderate in toxicity and CE below 0.5 g/kg dose 
level is safe to be used in the efficacy study especially for diabetes treatment
98
.
 
 
18. Prasanth kumar et al (2014) performed a study on acute and sub acute (28-day) 
oral assessment of ethanolic extract of celtis timorensis leaves in mice using OECD 
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425 guidelines whereas sub-acute toxicity study was carried out in rats by using 
OECD 407 guidelines. Mice where administered a single dose of  2000mg/ kg and  
5000 mg/kg orally in acute toxicity study. Then observed individually for first four 
hours, then over a period of 24 hours and at least once daily for 14 days. In the case 
of oral sub-acute toxicity studies, EECT was given orally at doses of 250, 500, 1000 
mg/kg body weight daily for 28 days to male and female rats respectively. General 
behavior, adverse effects and mortality were observed during the period of the study. 
Water intake, food consumption, relative organ weight, hematological and 
biochemical parameters and organ histopathological alterations are evaluated
99
. 
 
 
19. Behera et al (2012) examined the phyto-constituents and cardioprotective activity of 
Pongamia pinnata (PP) leaf extract (hydro-alcoholic) in experimentally induced 
myocardial infarction in Wistar Albino rats. Six groups of Wistar albino rats, each 
comprising six animals, were selected for the study. Group I served as a control, 
Group II rats were given isoproterenol (20 mg/100g, subcutaneously), and Group III 
rats were given Pongamia pinnata leaf extract (300 mg/kg). Groups IV, V and VI 
rats were given Pongamia pinnata leaf extract (100 mg/kg, 200 mg/kg and 300 
mg/kg, respectively) and isoproterenol (20 mg/100g subcutaneously) prior to MI 
induction. The transaminases (aspartate transaminase and alanine transaminase), 
lactate dehydrogenase (LDH) and creatine phosphokinase (CK), were estimated in 
both the plasma and heart tissues. Troponin T activity was separately estimated for 
plasma.during their study it is noticed that the Isoproterenol significantly increased 
the activities of CK, LDH and the transaminases in plasma with a concomitant 
decrease in these enzymes in tissue. Pretreatment with the hydro-alcoholic leaf 
extract of Pongamia pinnata at a dose of 300 mg/kg body weight for 30 days had a 
significant effect on the activities of marker enzymes compared to the other groups. 
Pongamia pinnata pretreatment may offer protection in experimental cardiotoxicity 
induced by isoproterenol
100
.
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20. Abi Beaulah et al (2014) reported that the Methanolic extract of Croton sparciflorus 
showed significant cardioprotective effect by lowering the serum levels of various 
biochemical parameters like CPK, LDH and transaminases in the selected model. 
The results obtained in the present work are in turn with histopathological 
examinations of heart tissue sections and are comparable with the standard 
cardioprotective drug. The results also suggests that the biologically active 
phytoconstituents such as flavonoids, glycosides, alkaloids present in the methanolic 
extract of plant which is confirmed from the qualitative analysis may be responsible 
for the significant cardioprotective activity
101
.
 
 
21. PakutharivuThangarajan et al (2015) demonstrated the effect of Pithecellobium 
dulce fruit peel in isoproterenol (ISO) induced myocardial infarction (MI) in adult 
male Wistar rats. Myocardial infarction was induced by intraperitoneal injection of 
isoproterenol (ISO) 2 mg/kg in experimental rats. Aqueous and ethanolic extract of 
Pithecellobium dulce fruit peel was administered intraperitoneally at a dose of 200 
mg/kg for a period of 14 days. On 14th day the rats were induced with ISO. Serum 
lipid profile, liver marker enzymes such as serum glutamate pyruvate transaminase 
(SGPT) and serum glutamate oxaloacetate transaminase (SGOT), cardiac marker 
enzymes such as creatine phosphokinase (CPK) and lactate dehydrogenase (LDH) 
were measured in the experimental rats along with histopathological studies of heart 
tissues. ISO-induced rats showed a significant increase in the activities of marker 
enzymes such as SGOT, SGPT, CPK and LDH. Pretreatment with aqueous and 
ethanolic extract of Pithecellobium dulce fruit peel, positively altered the activities 
of marker enzymes and the biochemical parameters in ISO-induced rats. Thus the 
study showed that Pithecellobium dulce possess cardioprotective effect in ISO 
induced MI in rats
102
.
 
 
22. Alam Firoj et al (2014) repoted that T. belerica possess potential to ameliorate the 
myocardial damage induced by isoproterenol in rat. . Myocardial damage was 
induced by subcutaneous administration of isoprenaline (85 mg/kg) for two 
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consecutive days. . Male wistar rats were administered Terminalia belerica (150 and 
300mg/kg/p.o.) for 28 days and metoprolol (meto, 10 mg/kg) for 28 days orally in 
their respective groups. A change in biomarkers levels reflects the influence of 
treatment. The creatine kinase (CK) activities were fallen in serum and elevated in 
heart tissue of animals treated with low and high doses of T.B as well as Metoprolol 
compared to ISO control. The enzymes-lactate dehydrogenase (LDH), alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) in serum activity 
were significantly reduced inserum with both and high doses of T.belerica while no 
change was noted in heart with both doses compared to ISO control. Hence it is 
concluded that T. belerica possess potential to ameliorate the myocardial damage 
induced by isoproterenol in rat
103
.
 
 
23. E. Sathyapriya et al (2012) studied the in vitro antiplatelet aggregation and 
thrombolytic activity of cheenalinga chendhuram (CLC) drug from mineral origine, 
which was showed effective at the dose of 300μg/ml and 75μg/ml respectively.so 
they conclude therefore, that CLC is an effective drug in the treatment of 
cardiovascular diseases and cerebrovascular accidents
104
.
 
 
24. Bhaargavi V et al (2016) investigated the thrombolytic potential of natural plants 
and their products. The invitro clot lysis activity was studied by taking various 
proportion of herbal mixtures and compare with streptokinase as positive control and 
isotonic normal saline as negative control. The aqueous extracts of Punica granatum, 
Zingiber officinale and Phyllanthus emblica on an average were able to dissolve 
37.42%, 30.03% and 34.31% of the clot respectively
105
.
 
 
25. A. Elumalai et al (2012) investigated with crude extract of Bogainvilla glara carried 
out to evaluate  its possible thrombolytic activity. The crude methanolic extract was 
found have significant thrombolytic activity at a dose of 800 micro gram/ ml with 
maximum effect comparable with the streptokinase as positive control and water as 
negative control
106
.
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26. Mubarak yusuf Ibrahim et al (2015) worked out an in-vitro thrombolytic model 
was used to check the clot lysis effect of the crude extract of B. pilosa, streptokinase 
was used as positive control and sterile water used as negative control. In this study 
model, methanoli extract of B.pilosa showed significant clot lysis activity with 
46.20±2.274 % when compared to positive control (82.60± 2.45 %) and negative 
control ( 11.29 ± 0.677 5). Base on these study results  they suggested that the 
thrombolytic activity of B.pilosa, could be considered as very promising and 
beneficia for the traditional medicine
107
.
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CHAPTER - III 
AIM AND OBJECTIVE OF THE STUDY 
 
Cardiovascular diseases (CVDs) are group of disorders of the heart and blood vessels and 
include coronary heart disease (heart attack), cerebrovascular disease, rheumatic heart 
disease and other conditions. Four out of five cardiovascular disease deaths are due to heart 
attacks and strokes.  
 
Cardiovascular Diseases are responsible for over 17.3 million deaths per year and are the 
leading causes of death in the world. Deaths due to heart attacks, strokes and other types of 
CVDs as a proportion of total cardiovascular deaths for males and females. 
 AIM:  
The primary aim of this study is to evaluate the cardiovascular assessment of dual herbal 
combination.  
To met the primary aim the following objectives are considered 
 To assess the acute and sub-acute toxicity study of the dual herbal combination 
 To determine the cardioprotective activity by isoproterenol induced  myocardial 
infarction in experimental animal model 
 To perform the thrombolytic activity by in-vitro screening method. 
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CHAPTER-IV 
PLAN OF WORK 
 
Proposed plan of work was carried out in the following stages: 
Phase I 
 Literature survey 
Phase II 
 Collection of herbal ingredients and raw materials. 
Phase III 
 Toxicological assessment 
 Acute toxicology (OECD 425) 
 Sub-acute toxicology (OECD 407) 
Phase IV 
 Pharmacological evaluation 
 Cardioprotective evaluation 
 In-vitro thrombolytic activity 
Phase V 
 Compilation of data and conclusion 
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CHAPTER – V 
 
MATERIALS AND METHODS 
 
5.1. Herbal Components 
 
Name of the herbal ingredients Name of the manufacturer 
 
Black seed oil 
Nigella’s herbal healthcare, Calicut, 
Kerala. 
Drug. lic. no.: 06/25D/2011 
 
Barley powder 
Ashtavaidya herbal pharma,  
Ettumanoor, Kerala. 
Mfg. lic. no.:FSSAI11312005001123 
 
Table 3: Name and manufacturer of the herbal ingredients 
The herbal mixture of nigella oil and barley water was prepared and stabilized with tween 
80 
  
5.2. Chemicals 
 
Name of the chemicals Name of the supplier 
Isoproterenol hydrochloride Micro labs limited, API division, 
Banglore-560105, Karnataka, India. 
Chloroform Nice chemicals, Kochi,Kerala 
Formaline Merk Millipore, India 
Normal saline  Baxter india, Haryana 
Tween 80 S D fine chemicals ltd, Mumbai 
Di sodium hydrogen 
orthophosphate (mono and dibasic) 
S D fine chemicals ltd, Mumbai 
 
Table 4: Name and supplier of the chemicals used  
Pharmacological assessment of dual herbal combination on cardiovascular system 
 
RVS College of Pharmaceutical Sciences, Sulur   44 
 
5.3. List of Instruments 
 
Name of instruments Name of the supplier 
Rota-rod Apparatus INCO, instruments and chemicals  
Cooks Pole Climbing Apparatus     MKM,Chennai 
Photo -Actometer  INCO, instruments and chemicals 
Heated plate analgesiometer INCO, instruments and chemicals 
 
. Table 5: Name and supplier of the instruments 
5.4. Experimental Animals 
Male and female  albino wistar rats (150- 200 g) used in the present study were procured 
from the small animals breeding station, Mannuthy, Kerala, India. They were housed in 
polypropylene cages under standard environmental conditions (12H dark /12H light cycles; 
temp., 25±2°C; 35-60% humidity, air ventilation) and were fed with standard pellet diet 
(M/s. Hindustan Lever Ltd., Mumbai, India) and fresh water ad libitum. The animals were 
acclimatized to the environment for two weeks prior to experiment use. The experiment was 
carried out according to the guidelines prescribed by Animal Welfare Board and with the 
prior approval of animal ethical committee. 
 
5.5. Approval of Protocol 
All the experimental procedures and protocols used in this study were reviewed and 
approved by the Institutional Animal Ethical Committee (IAEC) of RVS College Of 
Pharmaceutical Sciences,Sulur, Coimbatore constituted under Committee for Purpose of 
Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment 
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and Forests, Government of India (Reg. No. 1012/PO/c/CPCSEA). Ethical guidelines were 
strictly followed during all the experiments. 
 
METHODS 
5.6. Toxicological Evaluation 
5.6. A. Acute Toxicity Studies
99 
Oral acute toxicity studies of NSO+BW (Black Cumine Oil  + Barley Water) was carried 
out in female rat by using Organization for Economic Co-operation and Development 
(OECD) guideline 425. The rats were deprived food for 3 hour before oral administration of 
a single dose of the test samples. Doses of  5 ml of nigella sativa oil followed by 5 ml of 
barley water were given using oral gavage needle  to rats of group 1 and group 2 
respectively. All the test sample given animals were observed for general behavioral 
changes; toxicity symptoms and mortality after treatment for the first four (crucial) hours. 
Then over a period of 24 hours, there after daily for 14 days.  
5.7. B. Sub- Acute Toxicity Studies
 
Sub- acute 28-day repeated dose oral toxicity study was carried out according to OECD 407 
guidelines
2
. Both sexes of rats (150-200g) were divided into four different groups with 10 
animals (5 male and 5 female each).  
Group I :  Saline 10ml/kg  
 
Group II    :  Low dose     (0.5ml NSO +1 ml BW)  
   
Group III   :  Medium dose   (1 ml NSO + 2 ml BW) 
 
Group IV   :  High dose     (2 ml NSO + 4 ml BW) 
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All the groups were observed two time in a day for mortality and morbidity till the 
completion of experiment. The clinical signs and time of onset, duration of these symptoms, 
if any were recorded. The amount of food and water intake was noticed on every day and 
data were expressed as 7 days cumulative value. Body weights of the treatment groups were 
recorded once before the start of  dosing, once weekly during the period and finally on the 
day of sacrifice. At the end of the experiment (on 29
th
 day), blood samples were collected 
from overnight fasted rats by retro- orbital puncture method into EDTA coated or uncoated 
sample collecting tubes for hematological and biochemical analysis
99
. 
 
5.6. C. Hematological Parameters 
The EDTA mixed blood was used for the analysis of hematological parameters such as total 
hemoglobin (Hb), packed cell volume (PCV), WBC count, RBC count, differential count, 
MCV, MCH, MCHC, RDW, platelet count and MPV etc. 
 
5.6. D. Biochemical Parameters 
The serum was separated from the uncoated (EDTA) blood and the serum biochemical 
parameters including total cholesterol, creatinine, bilirubin total, alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), triglycerides (Tg), HDL, LHL, VLDL, 
CHO/HDL ratio were analyzed by using various biochemical laboratory analyzing methods 
. 
5.6. E. Histopathology 
On the 29
th
 day, all the animals were euthanized after blood collection for gross pathological 
examinations of all major organs such as liver, kidney, brain and heart were collected from 
the animals for histopathogical study. The collected organs were weighed and preserved in 
10 % neutral buffered formaline, trimmed and microne sized tissue sections were stained 
with appropriate staining agent (hematoxylin and eosin) for histopathological examination. 
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5.7. Pharmacological Studies 
5.7. A.  Assessment of Cardioprotective Activity
109 
5.6. A. I. Allocation of Groups And Experimental Protocol 
The rats were randomly divided into five groups with six rats in each group. 
Group I      :  Normal animals received saline 10ml/kg body weight with standard 
feed and water to allow ad libitum throughout the experimental 
period.  
 
Group II    :  The rats were orally fed normal saline once daily for 30 days and in 
addition, received isoproterenol (85mg/kg body weight) on the 29 and 
30 day at an interval of 24 h.  
 
 
Group III   :  Rats were pretreated with verapamil (5μmol/kg body weight, intera 
vein)   for a  of 14th day and 30th days only and in addition, received 
isoproterenol 85 mg/kg body weight on the 29 and 30 day at an 
interval of 24h. 
 
Group IV   :  Rats were pre-treated with NSO + BW for a period of 30 days and in 
addition, received isoproterenol 85mg/kg bw on the 29 and 30day at 
an interval of 24 h. 
 
5.7. A. II.  Induction of Myocardial Infarction 
 
At the end of experimental period, all the animals, except the normal untreated rats that 
served as the control group, were administered isoproterenol (ISO) 85 mg/kg, 
interaperitoneal injection for two consecutive days on the 31 and 32 day at an interval of 24 
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h. to induce myocardial injury After 48 hours rats were anaesthetized with anaesthetic ether, 
then sacrificed and the hearts were harvested for biochemical and histological studies. 
 
5.7. A. III.  Collection of Blood and Heart Tissues 
 
After treatment of 32
nd
 day, all the animals were sacrificed by cervical dislocation by mild 
chloroform anaesthesia and the fasting blood sample of each group were collected 
separately into sterilized blood collecting tubes, and allowed to coagulate for 30 min. at 37 
0
C. The clear serum obtained after centrifugation was used for the estimation of biochemical 
parameters like lactate dehydrogenase (LDH), creatine kinase (CK-MB), serum aspartate 
amino transferase (AST), and alanine aminotransferase (ALT). 
  
The heart was excised immediately and immersed in physiological saline. It was suspended 
in 10%) ice-cold 0.1 M phosphate buffer (pH 7.4) and cut into small pieces. 
 
5.7 A. IV. Histological Examinations 
The heart was excised immediately and washed with ice-cold saline; then fixed in 10% 
buffered formalin; 10% stored buffered formalin were embedded in paraffin; 5μm thick 
sections were cut and stained with hematoxylin and eosin. These sections were then 
examined under a light microscope for histological changes with the help of a veterinary 
pathologist. 
 
5.7. B. In-vitro Thrombolytic Activity
110 
5.7. B. I. Effect of NSO+BW on Clot Lysis 
 
 
Blood sample (500μl) was distributed in pre weighed sterile micro centrifuge tubes and 
incubated at 37 
0
C for 90min for clot formation. After clot formation, the serum was 
completely aspirated without disturbing the clot and the tubes were again weighed to 
determine the clot weight 
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Clot weight = Weight of the tube containing clot – Weight of the empty tube.  
 
To each micro centrifuge tube containing the pre weighed clot, 100μl of NSO+BW was 
added separately. As, a positive control 100μl of streptokinase (SK) and as a negative non 
thrombolytic control 100μl of distilled water  added separately to the different control tubes. 
All the tubes are then incubated at 37° C for 90 mins and observed for clot lysis. After 
incubation the released fluid was removed and the tubes were weighed again. The difference 
in weights taken before and after clot lysis were expressed as percentage of clot lysis as 
shown. 
 
% of clot lysis = (weight of released clot/ clot weight)* 100. 
5.8. Statistical Analysis 
All the results are expressed as mean ± SEM (standard error mean). Data obtained was 
analyzed by using one way ANOVA followed by dunnett’s test and p< 0.05 was considered 
as statistically significant.   
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CHAPTER – VI 
RESULTS AND DISCUSSION 
 
6.1. Acute Toxicity Study 
In acute toxicity study, oral administration of the NSO+BW at (0.5+1ml/kg and 1.5+4ml/kg) 
lower dose and higher dose did not produce any deaths and clinical signs of toxicity in 
experimental rats. Both the test doses does not show mortality and clinical signs of toxicity, 
therefore LD50 value of NSO+BW was found to be greater than higher dose. 
LD 50 determination is usually an initial step in the determination and evaluation of toxic 
characteristics of a substance in the preliminary drug screening. This initial assessment of 
toxic manifestation is one of the primary screening experiments performed with all lead 
compounds. 
  
Data from the acute toxicity study may provide; basic information on the mode of toxic 
action of substance; help in dose determination in animals; help arrive at a dose of new 
compound; and most importantly help to determine LD 50 values that provide many indices 
of potential types of drug activity. 
 
NSO+BW at a dose of 1.5+4ml/kg had no changes in Eye, Skin, Fur, Mucosal membrane, 
respiratory, Circulatory, Autonomic, CNS, Motor and Behavioral pattern were noted. 
The observed results show no signs of tremor, convulsion, salivation, diarrhea, lethargy and 
sleep etc (Table: 4) 
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Sl no 
 
Parameters 
 
Observations 
1 Reactivity Easy/normal 
2 Handling Did not resist, very easy to 
handle 
3 Palpebral closure Normal (eyes are open) 
4 Lacrimation No lacrimation 
5 Salivation No salivation 
6 Piloerection None/normal 
7 Hair coat Normal 
8 Bite marks None 
9 Nail status Normal 
10 Rearing activity Normal 
11 Clonic involuntary movement None 
12 Tonic involuntary movement None 
13 Gait Normal 
14 Movements Normal 
15 Arousal Normal (keeps guard up and 
engages in exploratory 
activity) 
16 Stereotype behaviour (preening, squeaking, 
shaking head and other repetitive behavior 
None 
17 Abnormal behaviour (squirming, running 
backwards, labored movements, squealing) 
 
None 
 
Table 6: Effect of NSO+BW on Autonomic Observations 
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6.2. Sub-Acute Toxicity Study 
 
In the repeated dose 28 days oral sub-acute toxicity study, there is no significant toxicity 
signs and mortality observed in the both sexes of rats treated at doses 0.5+1 ml, 1+2 ml and 
2+4 ml of body weight of NSO+BW. 
 
No treatment related changes in body weight were observed between the initial and final 
body weight of rats treated with NSO+BW and control (Table: 7). A similar lack of toxicity 
was noticed in the case of food and water consumption (Table: 5 and 6) during the period. 
There were no significant differences between groups of animals treated with NSO+BW and 
control in organ weight (Table: 8). 
 
6.2.1. Effect on Feed Intake 
 
Treatment 
group 
 
Sex 
 
Feed Intake (gms) 
Week 1 Week 2 Week 3 Week 4 
 
control 
Male 46.23±0.90 64.56±1.32 49.75±1.70 36.32±2.43 
Female 44.34±0.295 65.47±0.495 42.85±1.885 34.22±0.74 
LD 
Male 77.24±1.65 76.21±1.65 61.34±2.24 41.73±3.63 
Female 79.01±1.09 74.11±1.55 51.32±4.22 37.2±1.455 
MD 
Male 67.43±2.04 70.20±1.95 63.21±1.90 50.38±1.67 
Female 65.71±2.2 62.15±0.935 45.38±0.56 44.9±1.935 
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Values are expressed as mean ±SEM, n = 5 females and 5 males 
Table 7: Effect of combination of NSO+BW on Feed Intake in Rats-Sub-Acute Toxicity 
Study 
 
 
                                        
 
Fig 17: Graphical representation Effect of NSO+BW on feed intake in control and 
experimental rats (sub acute toxicity studies). 
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6.2.2. Effect on Water Intake 
 
 
Treatment 
group 
Water Intake(ml) 
Sex Week 1 Week 2 Week 3 Week 4 
Control Male 67.61±1.76 63.82±1.41 66.79±2.82 60.43±1.52 
Female 63.00±1.425 64.90±2.34 62.48±1.77 46.19±0.825 
LD Male 76.55±2.13 75.64±1.14 71.32±1.42 55.92±0.85 
Female 75.29±2.45 74.47±1.39 52.64±1.045 53.48±1.025 
MD Male 69.20±2.14 70.25±3.50 43.76±3.32 52.43±2.39 
Female 65.84±0.385 60.91±0.475 45.12±0.76 46.13±0.79 
HD Male 65.21±1.02 72.30±1.31 46.61±0.92 50.50±1.38 
Female 66.37±0.725 65.65±0.965 45.82±0.54 45.42±1.435 
Values are expressed as mean ±SEM, n = 5 females and 5 males 
Table 8: Effect of combination of NSO+BW on Water Intake in Rats-Sub-Acute 
Toxicity Study 
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Fig 18: Graphical representation Effect of NSO+BW on water intake in control and 
experimental rats (sub acute toxicity studies). 
6.2.3. Effect on Body Weight 
Treatment 
group 
 
Sex 
Body Weight (gms) 
Week 1 Week 2 Week 3 Week 4 
Normal 
 
Male 205.5±4.57 206.5±3.32 210.6±4.25 226.4±5.55 
Female 192.25±4.5 195±3.725 207±4.405 220.5±6.34 
LD Male 183±4.56 193±3.31 203.4±4.35 225±5.09 
Female 163.8±3.325 200.2±4.09 209±6.335 215±8.07 
MD Male 209±5.45 211±5.78 221.3±5.94 236.4±7.25 
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Female 206.75±1.65 200.25±2.015 216.25±2.52 219.5±1.84 
HD Male 231±5.66 240±4.32 254±6.45 266±4.45 
Female 230±5.4 231.25±4.26 237.75±2.92 260.25±3.52 
Values are expressed as mean ±SEM, n = 5 females and 5 males 
Table 9: Effect of combination of NSO+BW on Body Weight Gain in Rats-Sub-Acute 
Toxicity Study 
 
 
Fig 19: Graphical representation Effect of NSO+BW on body weights in control and              
experimental rats (sub acute toxicity studies). 
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6.2.4. Effect on Relative Organ Weight 
Organ 
weight (gms) 
Sex 
 
Treatment group 
Control LD MD HD 
Heart 
 
Male 0.71±0.03 0.67±0.03 0.75±0.04 0.69±0.02 
Female 0.65±0.02 0.74±0.05 0.75±0.05 0.70±0.075 
Liver 
 
Male 4.89±0.20 5.85±0.31 5.82±0.45 5.31±0.25 
Female 4.66±0.35 5.87±0.705 5.11±0.315 5.04±0.115 
Kidney 
 
Male 0.98±0.12 1.15±0.06 1.08±0.05 1.10±0.05 
Female 1.02±0.05 1.18±0.08 1.15±0.05 1.09±0.05 
Brain 
 
Male 1.45±0.05 1.55±0.05 1.65±0.06 1.67±0.05 
Female 1.53±0.02 1.61±0.09 1.55±0.075 1.52±0.05 
Values are expressed as mean ±SEM, n = 5 females and 5 males 
Table 10: Effect of combination of NSO+BW on organ weight in Rats-Sub-Acute 
Toxicity Study 
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Fig 20: Graphical representation Effect of NSO+BW on relative organ weight in 
control and experimental rats (sub acute toxicity studies). 
 
 
6.2. 5. Effect on Hematological Profile 
 
The hematological data of treated and control groups were summarized (table: 5) and 
concluded that the evaluated parmeters  such as total RBC, total WBC,HB, PCV, MCV, 
MCH, MCHC, RDW, MPV, Polymorph, Lymphocyte, Eosiniphils, Monocytes and platelet 
count etc are within normal range in both control and treated groups during the experimental 
period. 
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Hematological 
parameters 
Sex Treatment group 
Control LD MD HD 
Hemoglobin 
(g/dl) 
Male  14.74±0.67 14.92±0.58 14.75±0.64 15.01±0.42 
Female    15.68±0.21 16.38±0.70 16.9±0.28 16.45±0.63 
PCV (%) Male  46.43±1.86 53.31±1.75 53.42±1.44 50.50±1.90 
Female   47.36±2.03 52.28±2.14 54.92±2.28 52.6±3.08 
Total WBC 
Count ( 
x10
3
/µl) 
Male  8.84±0.68 9.54±0.70 9.18±0.62 9.46±0.41 
Female    10.48±0.15 10.80±0.43 9.695±0.57 10.85±0.38 
Total RBC 
Count ( 
x10
6
/µl) 
Male  4.72±0.63 4.91±0.25 4.96±0.23 5.1±0.17 
Female   5.14±0.59 5.98±0.36 6.74±0.24 6.9±0.41 
Polymorphs 
(%) 
Male  9.24±1.12 8.12±1.67 8.64±0.14 9.02±0.088 
Female   9.98±1.09 11.00±0.20 10.00±0.11 9.625±0.084 
Lymphocytes 
(%) 
Male  46.00±3.31 39.00±3.42 42.00±2.37 44.00±1.33 
Female    58.00±4.64 59.01±2.06 54.00±4.31 49.62±1.25 
Monocytes  
(%) 
Male  5.2±0.27 5.0±0.28 4.7±0.19 4.2±0.11 
Female   2.92±0.69 4.1±0.55 3.75±0.71 2.65±0.57 
Eosinophils  
(%) 
Male  2.72±0.28 2.40±0.34 2.45±0.51 2.61±0.66 
Female   2.52±0.20 2.50±0.27 3.17±0.19 3.75±.0.42 
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MCV Male  56.21±3.46 55.32±3.48 55.43±3.35 63.01±3.46 
Female   71.90±2.94 73.87±0.30 74.32±2.20 73.77±4.61 
MCH Male  20.21±1.07 20.15±0.68 21.8±0.09 21.04±0.78 
Female   25.31±3.53 26.42±0.50 25.2±1.28 26.05±1.92 
MCHC Male  33.07±0.27 32.15±1.13 31.24±1.56 32.19±1.64 
Female   30.68±0.23 31.17±0.87 30.95±0.85 30.25±1.51 
RDW Male  12.30±2.67 12.14±3.36 11.76±1.07 13.46±1.10 
Female   15.68±2.45 14.9±2.37 17.62±0.37 16.05±1.14 
Platelet count 
(x10
3
/µl) 
Male  710.34±30.01 819.32±26.24 892.28±29.14 901.71±20.56 
Female   734.23±31.22 725±27.78 749.25±31.26 768±25.71 
MPV Male  8.6±1.16 9.2±1.10 8.81±0.89 9.4±0.68 
Female   6.9±0.14 7.44±.019 7.65±0.26 6.00±0.37 
Values are expressed as mean ±SEM, n = 5 females and 5 males 
Table 11: Effect of combination of NSO+BW on Hematological Parameters in Rats-Sub-
Acute Toxicity Study 
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Fig 21: Graphical representation Effect of NSO+BW on hematological parameters in 
control and experimental rats (sub acute toxicity studies). 
 
        
Fig 22: Graphical representation Effect of NSO+BW on hematological parameters in 
control and experimental rats (sub acute toxicity studies). 
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Fig 23: Graphical representation Effect of NSO+BW on hematological parameters in 
control and experimental rats (sub acute toxicity studies). 
 
 
6.2. 6 .Effect on  Biochemical Profile 
 
The information in the biochemical parameters of the control group and treated groups were 
presented in table:6. In this sub acute oral toxicity study didn’t show any significant changes 
in the biochemical parameters of the  animal such as Bilirubin Total, Total Protein, 
SGOT(AST), SGPT(ALP), Creatinine and Lipid Profile including total cholesterol, 
triglycerides, HDL, LDL,  VLDL, CHOL/HDL ratio. 
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Biochemical 
parameteres 
SEX Treatment group 
Control  LD MD HD 
SGOT (U/L) Male  
 
135.22±4.66 156.51±1.21 150.43±3.20 171.22±3.03 
Female  
 
121.97±3.52 152.76±1.38 154.7±4.43 187.55±4.17 
SGPT (U/L) Male  40.12±2.28 45.21±1.88 47.38±1.42 43.04±1.26 
Female  41.02±3.05 42.1±0.98 44.23±0.05 42.63±0.04 
Total Protein 
(g/dl) 
Male  7.40±0.15 7.24±0.17 6.98±0.52 7.30±0.21 
Female  7.21±0.32 7.34±0.28 7.53±0.13 7.92±0.32 
Creatinine  
(mg/dl) 
Male  0.82±0.14 0.81±0.03 0.77±0.075 0.74±0.04 
Female  0.89±0.06 0.78±0.05 0.84±0.045 0.80±0.054 
Bilirubin 
Total (mg/dl) 
Male  0.83±`0.20 0.79±0.18 0.82±0.15 0.80±0.12 
Female  0.86±0.14 0.88±0.175 0.92±0.05 1.07±0.07 
Total 
cholesterol 
(mg/dl) 
Male  83.42±4.75 86.00±3.24 84.00±1.89 85±1.55 
Female  80.02±3.59 83.95±2.05 94.9±1.78 83.84±1.65 
Triglycerides 
(mg/dl) 
Male  89.69±8.13 164.45±7.18 169.71±8.12 160.08±5.13 
Female  141.55±10.89 160.88±15.36 155.44±3.21 158.04±1.07 
HDL (mg/dl) Male  14.2±0.88 21.63±1.36 20.15±1.52 34.31±1.09 
Female  26.47±0.45 29.98±1.68 41.3±2.24 33.37±2.47 
LDL (mg/dl) Male  20.90±1.58 26.27±2.64 30.4±1.91 23.53±2.06 
Female  21.61±1.41 16.88±1.35 16.63±1.72 14.12±0.25 
VLDL 
(mg/dl) 
Male  17.6±1.11 2.47±1.06 25.41±0.98 25.01±1.26 
Female  25.2± 34.04±1.68 29.55±2.24 31.18±1.49 
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CHOL/HDL 
Ratio 
Male  2.32±2.35 2.09±1.25 2.87±1.68 2.25±1.08 
Female  1.64±0.135 2.34±1.65 2.16±1.75 2.14±0.97 
Values are expressed as mean ±SEM, n = 5 females and 5 male 
Table 12: Effect of combination of  NSO+BW on Biochemical Parameters in Rats-Sub-
Acute Toxicity Study 
 
    
 
Fig 24: Graphical representation Effect of NSO+BW on serum biochemical profile in 
control and experimental rats (sub acute toxicity studies). 
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Fig 25: Graphical representation Effect of NSO+BW on serum lipid profile in control 
and experimental rats (sub acute toxicity studies). 
. 
 
6.2. C. Histopathological study 
  
Fig.26-29 showed the histopathological changes in the kidney, liver, heart and brain of 
control and experimental rats after 28-day sub-acute toxicity study along with the findings 
for fourteen days recovery period. Fig. 26 illustrated normal architecture of kidney of the 
control rats as well as NSO+BW treated group. Normal structural features suggesting the 
preserved renal integrity of  the sub-acute treatment groups. 
The liver, heart, kidney and brain exihibits the normal architecture indicating the absence of 
any treatment related toxicity. 
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                        A           B 
Fig 26: Histological sections of kidney from the control and maximum dose 
A-section of kidney treated with normal  saline, B-section of kidney treated 
 with NSO+BW (2+4 ml kg
-1
) 
 
                     
        A                             B 
Fig 27: Histological sections of liver from the control and maximum dose 
A-section of liver treated with normal saline, B-section of liver treated  
With NSO+BW (2+4 ml kg
-1
) 
 
                     
                                    A                                                         B 
Fig 28: Histological sections of heart from the control and maximum dose 
A-section of heart treated with normal saline, B-section of heart treated with 
 NSO+BW (2+4 ml kg
-1
) 
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                A                                                            B 
Fig 29: Histological sections of brain from the control and maximum dose 
A-section of brain treated with normal saline, B-section of brain treated 
 With NSO+BW (2+4 ml kg
-1
) 
  
 
6.3. Cardiac Protective Activity 
 
 
Parameters 
 
Treatment Group 
Normal Control 
(ISOonly) 
ISO+ Propranolol ISO+(NSO+BW) 
 
CK-MB (U/L) 
 
123.4±3.62 
 
174.25±5.39   
 
134.25±4.31 
 
130.75±4.50 
 
LDH (U/L) 
 
739.75±5.65 
 
1881.75±13.22 
 
942.47±10.15 
 
1025.12±9.32 
 
SGOT (U/L) 
 
135.22±4.66 
 
165.47±5.10 
 
126.27±5.38 
 
154.025±4.005 
 
SGPT (U/L) 
 
87.4±4.84 
 
151.1±5.61 
 
111.4±3.66 
 
74.8±4.33 
 
Table 13: Effect of NSO+BW on the level of serum cardiac markers and in normal and 
isoproterenol induced MI in rats. 
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Fig 30: Graphical representation of Effect of NSO+BW on myocardial marker 
enzymes in ISO- induced myocardial infarction. 
 
6.3. A. Effect on serum Creatininekinase (CK) 
 
Rats treated with ISO (85mg/kg/,IP,) for two consecutive days had serum CK level of 
(174.25±5.39 U/L) measured. This was significantly higher (P<0.05) when compared to 
serum levels of CK in normal control rats (123.4±3.62 U/L) and standard ie; 
propranolol(134.25±4.31). ISO rats treated with NSO+BW (1+2 ml) for 30 days had serum 
level CK of (130.75±4.50 U/L) measured. This was significantly lower (P<0.05) when 
compared to CK levels in Iso control rats (123.4±3.62 U/L) (Table:11). 
 
6.3. B. Effect on serum Aspartate transaminase (AST) 
 
Rats treated with ISO (85mg/kg/,IP,) for two consecutive days had serum AST level of 
(165.47±5.10 U/L) measured. This was significantly higher (P<0.05) when compared to 
serum levels of AST in normal control rats (135.22±4.66 U/L) and standard ie; 
propranolol(126.27±5.38). ISO rats treated with NSO+BW once daily( 1+2 ml) for 30 days 
had  
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serum level AST of (154.025±4.005 U/L) measured. This was significantly lower(P<0.05) 
when compared to AST levels in ISO control rats (165.47±5.10 U/L) (Table:11) 
 
6.3. C. Effect on serum Alanine transaminase (ALT) 
 
Rats treated with ISO (85mg/kg/,IP,) for two consecutive days had serum ALT level of 
(151.1±5.61U/L) measured. This was significantly higher (P<0.05) when compared to 
serum levels of ALT in normal control rats (87.4±4.84U/L) and standard ie; propranolol 
(111.4±3.66). ISO rats treated (1+2 ml p.o, once daily) for 30 days had serum vlevel ALT of 
(74.8±4.33U/L) measured. This was significantly lower(P<0.05) when compared to ALT 
levels in Iso control rats (151.1±5.61U/L) (Table:11). 
 
 
6.3. D. Effect on Serum Lactate dehydrogenase (LDH) 
 
Rats treated with ISO (85mg/kg/,IP,) for two consecutive days had serum LDH level of 
(1881.75±13.22 U/L) measured. This was significantly higher (P<0.05) when compared to 
serum levels of LDH in normal control rats (739.75±5.65 U/L) and standard ie; propranolol 
(942.47±10.15). ISO rats treated with NSO+BW (1+2 ml, p.o, once daily) for 30 days had 
serum level LDH of (1025.12±9.32U/L) measured. This was significantly lower (P<0.05) 
when compared to LDH levels in ISO control rats (1881.75±13.22 U/L) (Table:11). 
 
 
6.3. E. Histopathology of Cardioprotective Effect of NSO+BW 
 
Histopathological examination of the normal control rat heart showed the regular 
histological arrangements with clear striations of myocardial fibers without any cellular 
alterations because of degradation of necrosis( fig 26-A) . The rats in the group 2 (ISO only) 
showed the abnormal histological arrangements including several congestions, 
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subendocardial necrosis and abundant hyperplasia along with increased edematous 
intramuscular space (fig 26-B). The histology of  
 
heart of group 3 treated with standard drug ie; propranolol maintain the normal architecture 
with minute alteration in congestion and necrosis.  The same pattern of arrangements are 
observed in the rat heart treated with NSO+BW of (1+2ml kg
-1
) (fig 26- C&D.). 
 
 
 
                            A)    Normal control                                  B) ISO only 
 
                          C) Treated with std drug          D) Treated with NSO+BW 
     
Fig 31:  Histopathological section of heart after a treatment period. 
 
6.4. In-vitro Thrombolytic Activity 
 
The positive control ( streptokinase) after 90 min of incubation at 37 
0
C  showed 91.00% 
clot lysis with p< 0.0002. the negative control (distilled water) showed only 14.67% clot 
lysis. Percentage clot lysis obtained after the treatment with NSO+BW (Table 12).was 
noticed a n impressing result when compared with positive control ( significant, p<0.002). 
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Treatment group 
 
Percentage clot lysis (Mean ± S.D) 
Streptokinase 91.00±0.55 
Distilled water 14.67±0.92 
NSO+BW 84.79±1.25 
 
The values expressed as mean ± SD, p<0.0002and p<0.002 by t-test method 
Table 14: Result of thrombolytic assay 
 
 
Fig 32: Graphical representation of in-vitro thrombolytic activity of NSO+BW 
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DISCUSSION 
 
Acute toxicity and Sub-acute toxicity
97-99 
In the developing countries, herbal products are prepared from various medicinal plants 
have become famous in health care and obtained from natural sources. It is well known that 
the herbal medicines commonly contain more than one plant or active constituents and their 
therapeutic efficacy is not provided by a single group of compounds. Some of these 
compounds act synergistically to modify the bioavailability and efficacy of the active 
constituent
2
.  The bioactive compounds from the medicinal plant are concluded to be safe 
without knowing the possible health care benefits and thus commonly used as self 
medication. However, there is a defect on toxicological data of these compounds. So acute 
toxicity study is required to identify the range of doses and probable clinical signs evoked 
by the test compound in animal under investigation. Moreover it is a tool for calculating 
therapeutic index of a lead compound. 
For a positive judgement on safety of a lead compound animal toxicity study is extreamely 
important and to find adequate potential for development into pharmacological compound. 
The present study reveals the acute and sub-acute toxicity profile of black cumin oil and 
barley water as a nanoemulsion form. 
No morbidity and mortality were observed on 1.5+4ml/kg treated group throughout in the 
14 days observation period. In this study, the results showed no unwanted effects in acute 
dose administration groups. This indicates that the LD50 was found to be, greater than that 
of higher dose of administration. The sub-acute dose was selected based on the rats LD 50 
value, which is greater than that of acute oral single dose. 
In repeated dose 28- days oral toxicity study, there were no treatment related side effects 
were noticed in all the NSO+BW treated animals. The body weight changes are the markers 
of adverse effects of the drugs and chemicals. If the body weight loss occurred in more than 
10% of the initial body weight of the animal will be considered as statistically significant. 
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There were no significant differences in body weight gain and organ weight of both control 
and treated groups of both sexes. Physiological and pathological state of an animal is also 
explained by its organ weight. The liver, heart, kidney, spleen and lungs are the primary 
organs of the animal affected by the toxic metabolic reactions.   
It is also important to measure the food and water intake during the repeated dose toxicity 
determination. The proper intake of the supplements is necessary to evaluate the 
physiological status of the animal. Food and water consumption also did not affect 
abnormally during the experiment period. Thus, the results indicates there was no 
interruption in the diet metabolism. 
Changes in the hematological and biochemical parameters have a great indicative value for 
toxicity determination in preclinical study. There is no specific alterations in the 
hematological parameters (platelet count, RBC count, WBC count and HB etc) during the 
repeated dose study. SGOT and SGPT (transaminases) are key indicators of liver functions 
and they are considered as biomarkers to conclude probable toxicity of the testing product. 
Destruction of liver parenchyma cells will normally cause the elevated level of these 
enzymes in blood. In this study there were no significant changes observed in AST and ALT 
in control and treatment groups, which reveals that the formulation didn’t affect the liver 
physiology.  
Total protein level and total bilirubin level in blood also indicates the behavior of liver 
function. Between the experimental groups the unvaried ranges in the total protein and total 
bilirubin were noticed. The normal values of creatinine suggest that repeated administration 
of NSO+BW didn’t cause any damage to the kidney also. 
Histopathological studies furnish supportive evidence for biochemical and hematological 
results. No histopathologiacal alterations are shown in the various organs of the animal such 
as liver, kidney, brain and heart of the entire groups. Based on results, it is  inferred that, 
formulated NSO+BW will not produce any observed adverse effect level.  
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Cardioprotective Effect
109-115 
Heart contains an abundant concentration of diagnostic marker enzymes like CPK, LDH and 
transaminases (AST & ALT) and once the heart is metabolically damaged, they releases its 
content into the extra cellular fluid (ECF). Isoproterenol (ISO), a synthetic catecholamine, 
has cardio toxic effects on the myocardium. The effects of ISO on heart are mediated 
through β1- and β2- adrenoceptors. Both β1- and β2- adrenoceptors mediate the positive 
inotropic and chronotropic effects to β-adrenoceptor agonists. ISPH is well known to 
generate free radicals and to stimulate lipid peroxidation, which may be a causative factor 
for the irreversible damage to the myocardium. 
  
In the present study, Significant increase was noticed in the activities of cardiac markers like 
LDH, CK-MB, AST and ALT in plasma of ISPH-treated rats or increased concentration in 
serum confirm the onset of myocardial ischemia. Hence which may be the reflection of 
consequences of cellular injury due to lipid peroxides.  
CPK is a muscle specific enzyme mainly for heart and brain; therefore, its increased 
concentration in serum is may be the result of myocardial injury, cardiac insufficiency, 
arrhythmias and myocardial infarction
 
due to cytosolic Ca2+overload.
 
Calcium is an 
essential factor in phospholipase-associated degradation of membrane phospholipids,which 
leads to damage of mitochondrial membrane, and diminish electron transport along with the 
leakage of lysosomal enzymes. Treatment with Calcium antagonists like nifedipine, β-
adrenergic blocker- propranolol and lipid lowering drug like guggulsterone partially 
reversed the changes in sarcolemma enzymes and improve the Calcium uptake in the 
damaged heart. 
 
 
The levels of CK-MB was found to be 123.47 ± 3.62 in Group I normal rats which increased 
to 174.25 ± 5.39 when the rats were treated with ISPH. Then the rats on treatment 
continuously with the NSO+BW (1+2 ml) for 30 days, showed a decrease in the values, 
which were found to be 134.25 ± 4.31, which were comparable with the standard drug 
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Propranolol treated group whose values were found to be 130.75 ± 4.50. The levels of LDH 
was found to be 739.75 ± 5.65 in Group I normal rats which increased to 1881.75 ± 13.22 
when the rats are treated with ISPH. Then the rats on treatment continuously with the 
NSO+BW for 30 days, showed a decrease in the values, which were found to be 1025.12 ± 
9.32, which were comparable with the Propranolol treated group whose values were found 
to be 942.47 ± 10.15. 
 
Transaminase (AST and ALT) levels are a sensitive indicator of liver cell injury and are also 
correlates poorly with severity of cardiac disease also. AST is found in decreasing order of 
concentration in the liver, cardiac muscle, skeletal muscle, kidney, brain, pancreas, lungs, 
leucocytes and erythrocytes. ALT is maximally concentrated in liver and is relatively less 
specific for other muscle injuries. Both the enzymes released into the body in increasing 
quantity when the tissues are damaged. 
 
The levels of AST and ALT were found to be 135.22±4.66and 87.4±4.84in Group I 
normal rats which increased to 165.47±5.10and 151.1±5.61 when the rats were treated 
with ISPH respectively. Then the rats on treatment for 30 days continuously with the 
NSO+BW showed a decrease in the values, which was found to be 154.025±4.005 and 
74.8±4.33for Group IV which is comparable with the standard drug Propranolol treated 
group whose values were found to be 126.27±5.38and 111.4±3.66 ( Table  11). The 
elevated level of AST and ALT in the serum in Group III and Group IV suggested a 
potential protective effect of the NSO+BW against ISPH induced heart damage The 
tendency of these enzymes to return to near normal in NSO+BW administered group is a 
clear manifestation of the cardioprotective activity of the product.  
 
 
Histopathological Evaluation  
 
The evaluated histopathological studies suggested that ISO induced toxicity leads to serious 
changes in the histology of heart. The increased generation of lipid peroxidation products 
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and associated reactive oxygen species lead to distruct the integrity and other pathological 
changes in the heart.  
 
The results of histopathological studies suggest that ISP toxicity leads to serious changes in 
the histology of heart. The increased formation of lipid peroxidation products and associated 
reactive oxygen species lead to collapse in membrane integrity and other pathological 
changes in heart.  
 
The cardioprotective efficacy of a drug is predominantly depends on the ability of either 
reducing the pathological behavior, or maintaining the physiology of macro and micro level, 
which has been attributed by toxins. The membrane stabilizing property and suppression in 
peroxidase generation  action of the herbal components from nigella sativa and hordium 
vulgare might be helpful in alleviating the pathological changes caused by the isoproterenol 
hydrochloride in heart 
 
In-vitro Thrombolytic Effect 
104-107 
One of the important pathogenesis of acute coronary syndromes and vessel injury is 
thrombosis, which leads to the adherence of platelets and subsequent platelet activation. 
Platelet activation is absolutely necessary for the coagulation cascade of blood when normal 
blood vessels are injured. However, the interactions between platelets and collagen can also 
cause circulatory disorders, such as thrombosis, atherosclerosis, and myocardial infarction 
etc. Inhibition of the platelet-collagen interaction might be a promising approach to the 
prevention of such thrombosis. 
Herbal combined dietary consumption of nigella sativa fixed oil and barley water inhibits 
platelet aggregation in vitro; therefore, they may be used to treat or prevent some 
cardiovascular diseases. 
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CHAPTER -VII 
SUMMERY AND CONCLUSSION 
 
Development of Herbal nanoemulsion  in this study were optimized using tween 80 with the 
addition of cosurfactant ethanol 96% by high energy method. The formulated nanoemulsion 
was translucent homogenous with yellowish brown in colour and the average globule size is 
below 1000 nm. The studied nanoemulsion plays a key role in the cardiovascular protection. 
Treatment with single oral dose and repeated sub-acute doses didn’t arise any toxic signs in 
body weights, feed and water intake , biochemical, hematological and histopathological 
result also. Therefore the formulation selected to assess cardiovascular proective activity. 
In summary, it has been concluded from the biochemical and histopathological evidence 
that the the herbal combination of  black cumin oil and barley water have a potential to 
inhibit the cardio toxic effects induced by ISPH and possesses a significant medicinal value 
in the prophylactic treatment of MI. Efforts are in advancement to isolate and characterize 
the active principle, which is responsible for the cardioprotective efficacy  and thrombolytic 
activity of this valuable medicinal plants. The search for new pharmacological-active 
compounds for drug development is an important issue, as the trend toward using 
standardized plant compounds quality, safety and efficacy will continue. Therefore, all 
efforts have to be targeted to reveal the chemical-pharmacological profiles of herbal 
ingredients and fixed combinations and to rationalize their therapeutic application. 
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